Skip to main content
Journal cover image

Clinical utility of non-EpCAM based circulating tumor cell assays.

Publication ,  Journal Article
Austin, RG; Huang, TJ; Wu, M; Armstrong, AJ; Zhang, T
Published in: Adv Drug Deliv Rev
February 1, 2018

Methods enabling the isolation, detection, and characterization of circulating tumor cells (CTCs) in blood have clear potential to facilitate precision medicine approaches in patients with cancer, not only for prognostic purposes but also for prediction of the benefits of specific therapies in oncology. However, current CTC assays, which capture CTCs based on expression of epithelial cell adhesion molecule (EpCAM), fail to capture cells from de-differentiated tumors and carcinomas undergoing loss of the epithelial phenotype during the invasion/metastatic process. To address this limitation, many groups are developing non-EpCAM based CTC assays that incorporate nanotechnology to improve test sensitivity for rare but important cells that may otherwise go undetected, and therefore may improve upon clinical utility. In this review, we outline emerging non-EpCAM based CTC assays utilizing nanotechnology approaches for CTC capture or characterization, including dendrimers, magnetic nanoparticles, gold nanoparticles, negative selection chip or software-based on-slide methods, and nano-scale substrates. In addition, we address challenges that remain for the clinical translation of these platforms.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Adv Drug Deliv Rev

DOI

EISSN

1872-8294

Publication Date

February 1, 2018

Volume

125

Start / End Page

132 / 142

Location

Netherlands

Related Subject Headings

  • Pharmacology & Pharmacy
  • Neoplastic Cells, Circulating
  • Nanotechnology
  • Nanoparticles
  • Humans
  • Epithelial Cell Adhesion Molecule
  • Biomarkers, Tumor
  • 3214 Pharmacology and pharmaceutical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Austin, R. G., Huang, T. J., Wu, M., Armstrong, A. J., & Zhang, T. (2018). Clinical utility of non-EpCAM based circulating tumor cell assays. Adv Drug Deliv Rev, 125, 132–142. https://doi.org/10.1016/j.addr.2018.01.013
Austin, R Garland, Tony Jun Huang, Mengxi Wu, Andrew J. Armstrong, and Tian Zhang. “Clinical utility of non-EpCAM based circulating tumor cell assays.Adv Drug Deliv Rev 125 (February 1, 2018): 132–42. https://doi.org/10.1016/j.addr.2018.01.013.
Austin RG, Huang TJ, Wu M, Armstrong AJ, Zhang T. Clinical utility of non-EpCAM based circulating tumor cell assays. Adv Drug Deliv Rev. 2018 Feb 1;125:132–42.
Austin, R. Garland, et al. “Clinical utility of non-EpCAM based circulating tumor cell assays.Adv Drug Deliv Rev, vol. 125, Feb. 2018, pp. 132–42. Pubmed, doi:10.1016/j.addr.2018.01.013.
Austin RG, Huang TJ, Wu M, Armstrong AJ, Zhang T. Clinical utility of non-EpCAM based circulating tumor cell assays. Adv Drug Deliv Rev. 2018 Feb 1;125:132–142.
Journal cover image

Published In

Adv Drug Deliv Rev

DOI

EISSN

1872-8294

Publication Date

February 1, 2018

Volume

125

Start / End Page

132 / 142

Location

Netherlands

Related Subject Headings

  • Pharmacology & Pharmacy
  • Neoplastic Cells, Circulating
  • Nanotechnology
  • Nanoparticles
  • Humans
  • Epithelial Cell Adhesion Molecule
  • Biomarkers, Tumor
  • 3214 Pharmacology and pharmaceutical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences